Siegfried buys 95% stake in biotechnology firm DiNAMIQS

2023-05-05

并购细胞疗法基因疗法临床研究

Siegfried buys 95% stake in biotechnology firm DiNAMIQS

Preview

来源: Pharmaceutical Technology

DiNAMIQS focuses on the development of viral vectors for cell and gene therapies. Credit: ArtemisDiana via Shutterstock.com.

Preview

来源: Pharmaceutical Technology

Switzerland-based Siegfried has purchased a 95% stake in DiNAMIQS, a biotechnology firm that focuses on the development and production of viral vectors for cell and gene therapies.

Siegfried will leverage DiNAMIQS’ capabilities to commercial scale by constructing a facility that complies with good manufacturing practice standards.

The facility will be situated with DiNAMIQS’ existing operations at Bio-Technopark in Zurich-Schlieren, Switzerland, and is anticipated to become operational in 2025.

DiNAMIQS’ parent company, DiNAQOR, will own the remaining 5% stake in the firm.

The deal includes an option for Siegfried to purchase this remaining 5% five years after the acquisition.

The move represents Siegfried’s strategy to expand its presence in biologics, and provides important growth opportunities in the mid to long term.

DiNAMIQS will initially continue to run under its own name and as a mostly independent venture within Siegfried.

DiNAMIQS and its clients will take advantage of the integration of its drug substances production activities into Siegfried’s capabilities, as well as the capacities for the aseptic filling and completion of complex biological entities at its facilities in Hameln, Germany, and Irvine in the US.

Siegfried CEO Dr Wolfgang Wienand stated: “With this acquisition, we are entering the rapidly growing space of cell and gene therapies where viral vector-based technologies support the majority of clinical candidates in a rich development pipeline.

“In our view, this approach of an initial small-scale acquisition of a highly capable technology platform followed by flexible bolt-on investments into capabilities and capacities in line with actual market needs, provides significant value upside at reasonable entry costs.

“This is perfectly in line with our EVOLVE strategy and our track record of disciplined execution of value-adding mergers and acquisitions – and a further step towards our vision of creating a leading contract development and managing organisation in our space.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.

This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

By Cytiva Thematic

Preview

来源: Pharmaceutical Technology

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构